Market revenue in 2023 | USD 1,371.8 million |
Market revenue in 2030 | USD 1,917.8 million |
Growth rate | 4.9% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.64% in 2023. Horizon Databook has segmented the Europe point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of chronic diseases, along with an increasing demand for rapid diagnostics in the region, are some key factors driving the market growth. Furthermore, government initiatives toward the development of point-of-care diagnostics equipment are expected to fuel market growth. In addition, the launch of new products drives the growth of the market in the review period.
In July 2021, QuantuMDx Group Limited, a UK-based developer of advanced point-of-care diagnostics, introduced its Q-POC system - a rapid, PCR-based point-of-care diagnostic system. The system and its first test, a SARS-CoV-2 detection assay, have received CE-IVD marking under the In Vitro Diagnostics Directive (98/79/EC), allowing its use in Europe.
Q-POC is a portable PCR system that condenses an entire molecular diagnostic laboratory into a user-friendly, accessible, and cost-effective single device, providing quick molecular diagnostic results at the point of care within approximately 30 minutes. The system is designed to be utilized by front-line healthcare professionals and can be employed in various settings, including emergency rooms, ICUs, birthing centers, clinics, and pharmacies. This development aims to enhance accessibility and efficiency in point-of-care testing for healthcare providers and patients.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe point-of-care molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account